Fig. 3From: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraineMonthly mean change in monthly migraine headache days with prodromal symptoms. *p≤0.05 vs PBO; **p≤0.01 vs PBO; ***p≤0.001 vs PBO. GMB, galcanezumab; LS,least squares; PBO, placebo; SE, standard errorBack to article page